Medindia

X

AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting

Thursday, May 15, 2008 General News J E 4
Advertisement
QUEBEC CITY, May 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.(NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its Senior Vice Presidentand Chief Financial Officer, Dennis Turpin, CA, will present a companyoverview at the upcoming Rodman & Renshaw 5th Annual Global HealthcareConference on Tuesday, May 20, 2008 at 9:40 am (local time), in the AtlantiqueSalon - Meridional (2nd floor) of the Meridien Beach Plaza Hotel at the SeaClub, in Monaco.

A live webcast of this presentation will be available on AEterna Zentaris'website at www.aezsinc.com in the Investors section. A replay will also beavailable for a period of 30 days on the Company's website.

Also on Tuesday, May 20, 2008, Professor, Jurgen Engel, Ph.D., ExecutiveVice President and Chief Scientific Officer at AEterna Zentaris will make aposter presentation at the American Urological Association's Annual Meeting,from 10:30 am to 12:30 pm (Eastern Time) in Room 315 AB of the Orange CountyConvention Center in Orlando, Florida. Titled, "Luteinizing Hormone-ReleasingHormone (LHRH) Receptors in BPH as Potential Molecular Targets for Therapywith Cetrorelix", the presentation will focus on the Company's lead compound,cetrorelix, which could provide rapid and long lasting improvement of symptomsin men with benign prostatic hyperplasia.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused onendocrine therapy and oncology with proven expertise in drug discovery,development and commercialization. News releases and additional informationare available at www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
NeurogesX Reports First Quarter 2008 Results
S
Derma Sciences Reports First Quarter 2008 Results